Objective To investigate the expression of ribonucleotide reductase subunit Ml (RRM1) and nucleotide excision repair cross complementing genel (ERCC1) protein in non-small cell lung cancer (NSCLC) at ⅢB and Ⅳ phases as well as its forecast on therapeutic effects of trecombinant human endostatin (Endostar) combined with gemcitabine/cisplatin chemotherapy. Methods The expression levels of ERCC1 and RRM1 in tissue of 51 patients with lung cancer at ⅢB and Ⅳ phases were detected by immunohistochemistry. After the treatment of endostar combined with gemcitabine/cisplatin chemotherapy more than 4 weeks, the prognostic relationship between expression levels of different ERCC1 and RRM1 and NSCLC treatment was analyzed and compared. Results In NSCLC tissue, the positive rates of ERCC1 and RRM1 were 43.1% and 62.7%, respectively. RRM1 had a positive association with the expression of ERCC1 protein significantly . The effective rate of ERCC1 and RRM 1 expressions being negative groups was 72.2% , while that of both expressions being positive groups was 19.0% . Any positive expression of both groups was 58. 3% . The differences were statistically significant. The lifetime of patients with low ERCC1 and RRM 1 expressions was obviously higher than that with high expressions . Conclusion ERCC1 and RRM1 expressions can be considered as an index to judge the sensitivity and prognosis of endostar combined with gemcitabine/cisplatin chemotherapy to NSCLC patients.%目的 探讨核苷酸还原酶亚单位M1 (RRM1)和核苷酸切除修复交叉互补基因1(ERCC1)蛋白在ⅢB和Ⅳ期非小细胞肺癌(NSCLC)中的表达,及其对重组人血管内皮抑制素(恩度)联合吉西他滨/奈达铂化疗疗效的预测.方法 采用免疫组织化学方法检测51例ⅢB～Ⅳ期肺癌患者组织中ERCC1和RRM1的表达水平.经过4周期以上恩度联合吉西他滨/奈达铂方案化疗,分析比较不同ERCC1和RRM1表达水平与NSCLC治疗预后的关系.结果 NSCLC组织中ERCC1的阳性率为43.1％,RRM1的阳性率为62.7％.RRM1与ERCC1蛋白表达显著正相关.RRM1和ERCC1表达均为阴性组的有效率为72.2％；二者表达均为阳性组为19.0％；二者表达任一阳性组为58.3％,3组之间比较差异均有统计学意义；ERCC1和RRM1低表达的患者生存期明显长于高表达者.结论 ERCC1和RRM1的表达可作为NSCLC患者恩度联合吉西他滨/奈达铂方案化疗敏感性及其预后判断的指标之一.
展开▼
